The Role of Drug Metabolism in Drug Discovery: A Case Study in the Selection of an Oxytocin Receptor Antagonist for Development
Authors:
- Douglas J. PettiboneDPDouglas J. Pettibone
Open Access
- 1 March 1995
- journal article
- review article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 23 (2) , 124-130
Abstract
Drug discovery is a process involving multiple disciplines and interests. During the research phase of drug discovery, usually a large number of compounds are evaluated for biological activity and toxicological potential in animal species. Various types of problems with respect to pharmacodynamics, pharmacokinetics, and toxicity are commonly encountered at this stage. Drug metabolism, as a discipline participating in a drug discovery team, can play an important role in identifying factors underlying the problems, facilitate the optimal selection of compounds for further development, provide information on metabolites for possible improvement in drug design, and contribute to the identification of the appropriate animal species for subsequent toxicity testing. During the process of evaluating oxytocin receptor antagonists for further development for treatment of preterm labor, in vivo and in vitro drug metabolism studies conducted in rats, dogs, and monkeys contributed to the selection of L-368,899 as the development candidate on the basis of pharmacokinetic and metabolism observations. The presence of active N-demethylated metabolites of two other equipotent compounds in rats and dogs was found to be the major factor responsible for the discrepancy between oral bioavailability and efficacies observed for these 2 compounds. For L-368,899, a compound that demonstrated 20-40% oral bioavailability in rats, dogs, and chimpanzees, extensive first-pass metabolism rather than absorption was determined as the major factor responsible for the poor bioavailability (< 1%) in rhesus monkeys. In vitro metabolism studies with hepatic microsomes from rats, dogs, monkeys, and humans substantiated the conclusion that the rate of hepatic metabolism of L-368,899 in monkeys is faster than in the other species.Keywords
This publication has 14 references indexed in Scilit:
- 1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm LaborJournal of Medicinal Chemistry, 1994
- L‐368,899, a potent orally active oxytocin antagonist for potential use in preterm laborDrug Development Research, 1993
- Synthesis of oxytocin in amnion, chorion, and decidua may influence the timing of human parturition.Journal of Clinical Investigation, 1993
- Design, Synthesis and Some uses of Receptor-Specific Agonists and Antagonists of Vasopressin and OxytocinJournal of Receptor Research, 1993
- Orally active, nonpeptide oxytocin antagonistsJournal of Medicinal Chemistry, 1992
- Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural productJournal of Medicinal Chemistry, 1992
- Fetal and Maternal Oxytocin in Human ParturitionAmerican Journal of Perinatology, 1989
- Oxytocin Receptor Blockade: A New Principle in the Treatment of Preterm Labor?American Journal of Perinatology, 1989
- Inhibition of uterine contractions of premature labour with an oxytocin analogue. Results from a pilot studyBJOG: An International Journal of Obstetrics & Gynaecology, 1987
- Oxytocin receptors in the human uterus during pregnancy and parturitionAmerican Journal of Obstetrics and Gynecology, 1984